These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

707 related articles for article (PubMed ID: 18599488)

  • 1. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
    Song JH; Kandasamy K; Kraft AS
    J Biol Chem; 2008 Sep; 283(36):25003-13. PubMed ID: 18599488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids.
    Yang TM; Barbone D; Fennell DA; Broaddus VC
    Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.
    Huang S; Sinicrope FA
    Cancer Res; 2008 Apr; 68(8):2944-51. PubMed ID: 18413764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Rosato RR; Almenara JA; Coe S; Grant S
    Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
    Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
    Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1.
    Zhang C; Cai TY; Zhu H; Yang LQ; Jiang H; Dong XW; Hu YZ; Lin NM; He QJ; Yang B
    Mol Cancer Ther; 2011 Jul; 10(7):1264-75. PubMed ID: 21566062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined treatment with ABT-737 and VX-680 induces apoptosis in Bcl-2- and c-FLIP-overexpressing breast carcinoma cells.
    Choi JE; Woo SM; Min KJ; Kang SH; Lee SJ; Kwon TK
    Oncol Rep; 2015 Mar; 33(3):1395-401. PubMed ID: 25592064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The novel Bcl-2 inhibitor ABT-737 is more effective in hypoxia and is able to reverse hypoxia-induced drug resistance in neuroblastoma cells.
    Klymenko T; Brandenburg M; Morrow C; Dive C; Makin G
    Mol Cancer Ther; 2011 Dec; 10(12):2373-83. PubMed ID: 22006676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
    Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
    Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upregulation of Death Receptor 5 and Production of Reactive Oxygen Species Mediate Sensitization of PC-3 Prostate Cancer Cells to TRAIL Induced Apoptosis by Vitisin A.
    Shin D; Kwon HY; Sohn EJ; Nam MS; Kim JH; Lee JC; Ryu SY; Park B; Kim SH
    Cell Physiol Biochem; 2015; 36(3):1151-62. PubMed ID: 26111475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.
    Wang X; Chen W; Zeng W; Bai L; Tesfaigzi Y; Belinsky SA; Lin Y
    Mol Cancer Ther; 2008 May; 7(5):1156-63. PubMed ID: 18483303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions.
    Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC
    J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucocorticoid receptor antagonist sensitizes TRAIL-induced apoptosis in renal carcinoma cells through up-regulation of DR5 and down-regulation of c-FLIP(L) and Bcl-2.
    Min KJ; Jang JH; Lee JT; Choi KS; Kwon TK
    J Mol Med (Berl); 2012 Mar; 90(3):309-19. PubMed ID: 22008998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnolol Enhances the Therapeutic Effects of TRAIL through DR5 Upregulation and Downregulation of c-FLIP and Mcl-1 Proteins in Cancer Cells.
    Woo SM; Min KJ; Kwon TK
    Molecules; 2020 Oct; 25(19):. PubMed ID: 33050112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulation of intracellular anti-apoptotic proteins, particularly c-FLIP by therapeutic agents; the novel view to overcome resistance to TRAIL.
    Hassanzadeh A; Farshdousti Hagh M; Alivand MR; Akbari AAM; Shams Asenjan K; Saraei R; Solali S
    J Cell Physiol; 2018 Oct; 233(10):6470-6485. PubMed ID: 29741767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-737 synergizes with bortezomib to induce apoptosis, mediated by Bid cleavage, Bax activation, and mitochondrial dysfunction in an Akt-dependent context in malignant human glioma cell lines.
    Premkumar DR; Jane EP; DiDomenico JD; Vukmer NA; Agostino NR; Pollack IF
    J Pharmacol Exp Ther; 2012 Jun; 341(3):859-72. PubMed ID: 22393246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
    Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunosensitization with a Bcl-2 small molecule inhibitor.
    Begley J; Vo DD; Morris LF; Bruhn KW; Prins RM; Mok S; Koya RC; Garban HJ; Comin-Anduix B; Craft N; Ribas A
    Cancer Immunol Immunother; 2009 May; 58(5):699-708. PubMed ID: 18807035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K; Huang S; Sinicrope FA
    Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.